Fluorodeoxyglucose-PET in the management of malignant melanoma

被引：43

作者：

Kumar, R ^{[1
]}

Mavi, A ^{[1
]}

Bural, G ^{[1
]}

Alavi, A ^{[1
]}

机构：

[1] Hosp Univ Penn, Div Nucl Med, Dept Radiol, Philadelphia, PA 19104 USA

来源：

RADIOLOGIC CLINICS OF NORTH AMERICA | 2005年 / 43卷 / 01期

关键词：

D O I：

10.1016/j.rcl.2004.09.011

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 [临床医学]; 100207 [影像医学与核医学]; 1009 [特种医学];

摘要：

Malignant melanoma is being diagnosed with an increasing incidence thoughout the world in recent years. It is curable by surgical excision in early stages of the disease and therefore, early diagnosis and treatment is essential for optimal outcome and can result in decreased morbidity and mortality from this cancer. The role of PET particularly in the diagnosis and initial staging has not been investigated adequately so far. This review focuses on clinical applications of PET in patients with malignant melanoma and discusses the role of fluorodeoxyglucose-PET in the initial staging and restaging by identifying metastatic and recurrent disease sites and the impact of this technique in the management of these patients. It summarizes the existing data evaluating the clinical significance of PET in the assessment of patients with malignant melanoma.

引用

页码：23 / +

页数：12

共 40 条

[1]

Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma [J].

Acland, KM ;

Healy, C ;

Calonje, E ;

O'Doherty, M ;

Nunan, T ;

Page, C ;

Higgins, E ;

Russell-Jones, R .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2674-2678

[2]

The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma [J].

Acland, KM ;

O'Doherty, MJ ;

Russell-Jones, R .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (04) :606-611

[3]

*AM CANC SOC, 2004, CANC FACTS FIG 2002

[4]

Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system [J].

Balch, CM ;

Soong, SJ ;

Gershenwald, JE ;

Thompson, JF ;

Reintgen, DS ;

Cascinelli, N ;

Urist, M ;

McMasters, KM ;

Ross, MI ;

Kirkwood, JM ;

Atkins, MB ;

Thompson, JA ;

Coit, DG ;

Byrd, D ;

Desmond, R ;

Zhang, YT ;

Liu, PY ;

Lyman, GH ;

Morabito, A .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3622-3634

[5]

POSITRON EMISSION TOMOGRAPHY AND ULTRASONOGRAPHY - A COMPARATIVE RETROSPECTIVE STUDY ASSESSING THE DIAGNOSTIC VALIDITY IN LYMPH-NODE METASTASES OF MALIGNANT-MELANOMA [J].

BLESSING, C ;

FEINE, U ;

GEIGER, L ;

CARL, M ;

RASSNER, G ;

FIERLBECK, G .

ARCHIVES OF DERMATOLOGY, 1995, 131 (12) :1394-1398

[6]

Crippa F, 2000, J NUCL MED, V41, P1491

[7]

Positron emission tomography in the detection and management of metastatic melanoma [J].

Damian, DL ;

Fulham, MJ ;

Thompson, E ;

Thompson, JF .

MELANOMA RESEARCH, 1996, 6 (04) :325-329

[8]

Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma [J].

Eigtved, A ;

Andersson, AP ;

Dahlstrom, K ;

Rabol, A ;

Jensen, M ;

Holm, S ;

Sorensen, SS ;

Drzewiecki, KT ;

Hojgaard, L ;

Friberg, L .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (01) :70-75

[9]

Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II [J].

Fink, AM ;

Holle-Robatsch, S ;

Herzog, N ;

Mirzaei, S ;

Rappersberger, K ;

Lilgenau, N ;

Jurecka, W ;

Steiner, A .

MELANOMA RESEARCH, 2004, 14 (02) :141-145

[10]

A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy [J].

Finkelstein, SE ;

Carrasquillo, JA ;

Hoffman, JM ;

Galen, B ;

Choyke, P ;

White, DE ;

Rosenberg, SA ;

Sherry, RM .

ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (08) :731-738

← 1 2 3 4 →